Related Experiment Video
Updated: Jun 21, 2025
Engineering Adherent Bacteria by Creating a Single Synthetic Curli Operon
Published on: November 16, 2012
Path to bacteriotherapy: From bacterial engineering to therapeutic perspectives
Jinling Liu1, Chongsheng He2, Wenzhi Tan3
1The Affiliated Xiangtan Central Hospital of Hunan University, School of Biomedical Sciences, Hunan University, Changsha 410082, China; College of Biology, Hunan University, Changsha 410082, China.
Abstract:
The major reason for the failure of conventional therapies is the heterogeneity and complexity of tumor microenvironments (TMEs). Many malignant tumors reprogram their surface antigens to evade the immune surveillance, leading to reduced antigen-presenting cells and hindered T-cell activation. Bacteria-mediated cancer immunotherapy has been extensively investigated in recent years. Scientists have ingeniously modified bacteria using synthetic biology and nanotechnology to enhance their biosafety with high tumor specificity, resulting in robust anticancer immune responses. To enhance the antitumor efficacy, therapeutic proteins, cytokines, nanoparticles, and chemotherapeutic drugs have been efficiently delivered using engineered bacteria. This review provides a comprehensive understanding of oncolytic bacterial therapies, covering bacterial design and the intricate interactions within TMEs. Additionally, it offers an in-depth comparison of the current techniques used for bacterial modification, both internally and externally, to maximize their therapeutic effectiveness. Finally, we outlined the challenges and opportunities ahead in the clinical application of oncolytic bacterial therapies.
Insights
Engineered bacteria offer a novel approach to cancer immunotherapy by overcoming tumor microenvironment complexity. This review details bacterial design and modification strategies for enhanced cancer treatment efficacy.
Area of Science:
- Biotechnology
- Immunology
- Oncology
Background:
- Tumor microenvironments (TMEs) present significant challenges to conventional cancer therapies due to their heterogeneity and complexity.
- Malignant tumors often evade immune surveillance by altering surface antigens, which reduces antigen-presenting cells and impairs T-cell activation.
- Bacteria-mediated cancer immunotherapy is an emerging field that leverages engineered bacteria to elicit anticancer immune responses.
Purpose of the Study:
- To provide a comprehensive review of oncolytic bacterial therapies.
- To discuss bacterial design strategies and their interactions within the TME.
- To compare current techniques for bacterial modification to enhance therapeutic effectiveness.
Main Methods:
- Review of existing literature on bacteria-mediated cancer immunotherapy.
- Analysis of synthetic biology and nanotechnology approaches for bacterial engineering.
- Examination of therapeutic payload delivery using engineered bacteria.
- Comparison of internal and external bacterial modification techniques.
Main Results:
- Engineered bacteria can be designed for enhanced biosafety and tumor specificity.
- Bacteria can effectively deliver therapeutic proteins, cytokines, nanoparticles, and chemotherapeutic drugs.
- Modified bacteria can elicit robust anticancer immune responses by overcoming TME challenges.
- Various internal and external modification strategies exist to maximize therapeutic efficacy.
Conclusions:
- Oncolytic bacterial therapy holds significant promise for cancer treatment by addressing TME complexity.
- Further research and development in bacterial design and modification are crucial for clinical translation.
- Challenges and opportunities in the clinical application of oncolytic bacterial therapies require careful consideration.
Related Concept Videos
01:30Lytic Cycle of Bacteriophages
00:57Antibiotic Selection
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
01:30Bacterial Signaling
00:46Bioremediation